Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicotinate
Drug ID BADD_D01563
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
Marketing Status approved; investigational; nutraceutical
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 937
TTD Drug ID Not Available
NDC Product Code 72919-420; 59651-018; 59651-019; 62135-497; 71741-047; 47335-613; 50268-584; 62135-498; 65162-321; 65162-323; 68180-222; 68180-223; 62331-016; 68180-221; 71741-020; 47335-539; 47335-614; 71740-001; 71740-201; 62704-0027; 65162-322; 51552-0559; 62175-322; 33342-189; 59651-020; 62175-320; 25441-0095; 65372-1194; 33342-187; 51407-267; 51407-268
UNII 2679MF687A
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H4NO2-
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Xanthoma23.03.03.047; 14.08.04.010--Not Available
Metabolic syndrome05.06.02.007; 24.08.02.014; 14.06.02.007--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhage24.07.01.002--Not Available
Cystoid macular oedema06.04.06.010; 12.02.02.005--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Hyperinsulinism14.06.03.007; 05.06.03.007--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages